The aim of this study was to verify that subcutaneous lymph node transplantation inducing lymphatic regeneration is possible in healthy adult rats, in analogy to results obtained in other species. This rat model was used to determine the effects of lymph node fragmentation as well as sheep erythrocytes and platelet-rich plasma injection on the regeneration of the transplanted lymph nodes. The results show for the first time that the rat is an adequate model to study the regeneration of transplanted lymph nodes. Lymph node fragmentation seems to affect transplant regeneration negatively. An immune challenge by injection of sheep erythrocytes in the drainage area of the transplanted lymph nodes does not improve fragment regeneration. However, injection of syngeneic platelet-rich plasma containing several growth factors resulted in an improvement in regeneration. Lymph node fragment regeneration, although still experimental, could be relevant for lymphedema prevention. Acquired lymphedema has a high prevalence in developed countries as a consequence of the removal and/or radiotherapy of tumor-draining lymph nodes in cancer patients. This disease causes lifelong disability due to chronic swelling and increased risk of infections. It currently lacks an effective treatment.

Keywords:
Lymph node transplant, Lymphatic vessel, Platelet-rich plasma, Growth factors, Lymphedema prevention model
1.
Levick JR: Capillary filtration-absorption balance reconsidered in light of dynamic extravascular factors. Exp Physiol 1991;76:825–857.
2.
Lämmermann T, Sixt M: The microanatomy of T-cell responses. Immunol Rev 2008;221:26–43.
3.
Williams AF, Franks PJ, Moffatt CJ: Lymphoedema: estimating the size of the problem. Palliat Med 2005;19:300–313.
4.
Moffatt CJ, Franks PJ, Doherty DC, Williams AF, Badger C, Jeffs E, Bosanquet N, Mortimer PS: Lymphoedema: an underestimated health problem. QJM 2003;96:731–738.
5.
Pabst R, Rothkotter HJ: Regeneration of autotransplanted lymph node fragments. Cell Tissue Res 1988;251:597–601.
6.
Blum KS, Radtke C, Knapp WH, Pabst R, Gratz KF: SPECT-CT: a valuable method to document the regeneration of lymphatics and autotransplanted lymph node fragments. Eur J Nucl Med Mol Imaging 2007;34:1861–1867.
7.
Pabst R, Westermann J, Rothkotter HJ: Immunoarchitecture of regenerated splenic and lymph node transplants. Int Rev Cytol 1991;128:215–260.
8.
Rothkotter HJ, Pabst R: Autotransplantation of lymph node fragments. Structure and function of regenerated tissue. Scand J Plast Reconstr Surg Hand Surg 1990;24:101–105.
9.
Tammela T, Saaristo A, Holopainen T, Lyytikka J, Kotronen A, Pitkonen M, Abo-Ramadan U, Yla-Herttuala S, Petrova TV, Alitalo K: Therapeutic differentiation and maturation of lymphatic vessels after lymph node dissection and transplantation. Nat Med 2007;13:1458–1466.
10.
Han J, Meng HX, Tang JM, Li SL, Tang Y, Chen ZB: The effect of different platelet-rich plasma concentrations on proliferation and differentiation of human periodontal ligament cells in vitro. Cell Prolif 2007;40:241–252.
11.
Ogino Y, Ayukawa Y, Tsukiyama Y, Koyano K: The effect of platelet-rich plasma on the cellular response of rat bone marrow cells in vitro. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005;100:302–307.
12.
Yazawa M, Ogata H, Kimura A, Nakajima T, Mori T, Watanabe N: Basic studies on the bone formation ability by platelet rich plasma in rabbits. J Craniofac Surg 2004;15:439–446.
13.
Jila A, Kim H, Nguyen VP, Dumont DJ, Semple J, Armstrong D, Seto E, Johnston M: Lymphangiogenesis following obstruction of large postnodal lymphatics in sheep. Microvasc Res 2007;73:214–223.
14.
Mäkinen T, Norrmen C, Petrova TV: Molecular mechanisms of lymphatic vascular development. Cell Mol Life Sci 2007;64:1915–1929.
15.
Alitalo K, Tammela T, Petrova TV: Lymphangiogenesis in development and human disease. Nature 2005;438:946–953.
16.
Aloisi F, Pujol-Borrell R: Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol 2006;6:205–217.
17.
Mebius RE: Lymphoid organogenesis: educating stroma. Immunol Cell Biol 2007;85:79–80.
18.
Sasaki K, Pabst R, Rothkotter HJ: Development of the high endothelial venule in rat lymph node autografts. Anat Rec 1994;238:473–479.
19.
Ahrendt M, Hammerschmidt SI, Pabst O, Pabst R, Bode U: Stromal cells confer lymph node-specific properties by shaping a unique microenvironment influencing local immune responses. J Immunol 2008;181:1898–1907.
20.
Ma B, Jablonska J, Lindenmaier W, Dittmar KE: Immunohistochemical study of the reticular and vascular network of mouse lymph node using vibratome sections. Acta Histochem 2007;109:15–28.
21.
Boyapati L, Wang HL: The role of platelet-rich plasma in sinus augmentation: a critical review. Implant Dent 2006;15:160–170.
22.
Stacker SA, Farnsworth RH, Karnezis T, Shayan R, Smith DP, Paavonen K, Davydova N, Caesar C, Inder R, Baldwin ME, McColl BK, Roufail S, Williams RA, Hughes RA, Alitalo K, Achen MG: Molecular pathways for lymphangiogenesis and their role in human disease. Novartis Found Symp 2007;281:38–43; discussion 44–53, 208–209.
23.
van den Dolder J, Mooren R, Vloon AP, Stoelinga PJ, Jansen JA: Platelet-rich plasma: quantification of growth factor levels and the effect on growth and differentiation of rat bone marrow cells. Tissue Eng 2006;12:3067–3073.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.